RxDoctor Payments DataLook up a doctor →

Corey Diamond, MD

Internal Medicine · Jonesboro, ARNPI 1811983398

Payments from drug & device makers

$7,725in general payments, 2019–2025

Across 576 payments — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$991
  • GSK$844
  • AbbVie$784
  • Astellas Pharma US Inc$684
  • Amgen$647
  • Johnson & Johnson$446
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,720100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,725 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$267,721
Medicare patients
2,075
Services billed
5,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$161,496
OzempicSemaglutide107$102,665
JanuviaSitagliptin Phosphate86$75,938
JardianceEmpagliflozin70$49,567
FarxigaDapagliflozin Propanediol57$38,932
XifaxanRifaximin12$35,958
XareltoRivaroxaban44$29,595
MounjaroTirzepatide27$28,530
TrulicityDulaglutide23$28,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$26,839
MyrbetriqMirabegron43$25,738
LinzessLinaclotide35$24,327
Combivent RespimatIpratropium/Albuterol Sulfate34$18,648
GemtesaVibegron22$16,832
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$16,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$991$170,556229 claims
Novo NordiskOzempic$301$102,665107 claims
MerckJanuvia, Belsomra$222$80,51597 claims
Boehringer IngelheimJardiance, Combivent Respimat$265$68,215104 claims
Lilly USA, LLCMounjaro, Trulicity$216$56,81850 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$844$49,230105 claims
AstraZenecaFarxiga$371$38,93257 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$229$35,95812 claims
Johnson & JohnsonXarelto, Invokana$446$35,94756 claims
Astellas Pharma US IncMyrbetriq$684$25,73843 claims
AbbVieLinzess$784$24,32735 claims
Sumitomo Pharma America, Inc.Gemtesa$24$16,83222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →